세계의 자궁경부암 진단 시장 규모는 2022년 81억 달러에 달하며, 2030년에는 최대 130억 달러에 달할 것으로 예상됩니다. 자궁경부암 진단 시장은 2023-2030년의 예측 기간 중 6.3%의 CAGR을 보일 것으로 예상됩니다.
자궁경부암 진단의 일환으로 자궁경부암 및 전암성 질환을 진단하고 모니터링하기 위해 다양한 검사와 기술이 사용되고 있습니다. 자궁경부암의 병기를 확인하기 위해 림프절 생검, 방광경 검사, 항문경 검사, PET-CT(Positron Emission Tomography-computed tomography)와 같은 영상 검사 등의 추가 검사가 시행됩니다.
여성에게 자궁경부암은 대표적인 악성 종양입니다. 최근 몇 년동안 이환율과 사망률 증가와 함께 뚜렷한 회춘 추세를 보이고 있습니다. 자궁경부암은 병인(病因)이 명확하고 조기에 발견하면 치료할 수 있는 유일한 암입니다. 예를 들어 New Horizon Health가 개발한 CerviClear 테스트는 세계 최초의 소변을 통한 HPV 검출 및 자궁경부암 검진 테스트다.
비침습적인 가정용 소변 자가 채취를 실현하고 14가지 고위험군 HPV 바이러스를 모두 포괄하는 유일한 솔루션입니다. 이 제품은 이미 CE 마크를 획득하여 홍콩과 그레이터 베이 지역에서 도입이 가능합니다.
자궁경부암은 가장 예방 가능한 암 중 하나이며, 매년 인도 여성 중 약 77,000명이 사망하는 원인이 되고 있습니다. 예를 들어 2023년 4월 암 인식, 예방 및 조기 발견을 촉진하기 위한 비영리 단체인 Cancer Awareness Prevention and Early Detection Trust(CAPED)와 Roche Diagnostics India는 암 인식, 예방 및 조기 발견을 촉진하기 위한 양해각서(MoU)를 체결하였습니다. MoU).
CAPED와의 관계는 자궁경부암이라는 질병에 대한 사회적 낙인을 없애고 자궁경부암 검진에 대한 인식을 높이기 위한 로슈진단 인도의 최근 노력 중 하나입니다. 로슈진단은 세계에서 자궁경부암 발병률을 낮추기 위해 노력하고 있습니다.
자궁경부암 진단 검사의 가격은 특정 검사, 장소, 의료 시설의 환경, 존재하는 의료 시스템 등 여러 가지 변수에 따라 달라질 수 있습니다. 자궁경부 세포진 검사는 장소와 의료 전문가에 따라 20달러에서 100달러의 비용이 들 수 있습니다.
또한 HPV DNA 검사는 검사 기관과 정확한 검사 방법에 따라 50달러에서 200달러 이상의 비용이 소요됩니다. 자궁경부 세포진 검사는 지역과 의료 전문가, 검사 중 추가 시술에 따라 200달러에서 800달러의 비용이 발생할 수 있습니다.
COVID-19 팬데믹은 자궁경부암 진단 시장에 큰 영향을 미쳤습니다. 전염병은 의료 시스템에 압력을 가하고 자궁경부암 진단 서비스 이용을 제한하고 있습니다.
자궁경부 세포진 검사, HPV 검사, 자궁경부 세포진, 생검 등 진단 검사의 지연은 자원 부족, 의료기관의 과도한 업무 부담, COVID-19 대응 업무에 대한 인력 배분 등이 원인으로 지목되고 있습니다.
2023년 현재 COVID-19 상황이 회복되고 모든 환자가 의료 시설에 접근할 수 있게 되면서 자궁경부암 진단 시장을 주도하고 있습니다.
러시아·우크라이나 분쟁이 자궁경부암 진단 시장에 미치는 영향은 복잡하고 다면적입니다. 전투로 인해 사람들이 피난을 떠나고, 교통이 끊기고, 군 검문소가 설치될 수 있습니다. 이러한 장애물은 의료 시설에 대한 접근을 제한하고 사람들이 자궁경부암 진단 및 기타 의료 서비스를 신속하게 받는 데 어려움을 겪을 수 있습니다.
또한 분쟁이 발생하면 의료 자원과 노력이 외상 치료, 긴급 대응, 응급의료 수요에 집중되는 방향으로 전환되었습니다. 그 결과, 자궁경부암 검진 캠페인이나 자궁경부암 검진 프로그램 등 검진율을 낮추고 진단을 미루게 하는 공중보건 대책이 줄어들었습니다.
The Global Cervical Cancer Diagnostics Market size reached USD 8.1 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 13 billion by 2030. The cervical cancer diagnostics market is expected to exhibit a CAGR of 6.3% during the forecast period 2023-2030.
A variety of tests and techniques are employed in the diagnosis and monitoring of cervical cancer and precancerous diseases as part of cervical cancer diagnostics. Additional procedures, such as lymph node biopsy, cystoscopy, proctoscopy or imaging tests like PET-CT (positron emission tomography-computed tomography), are carried out to ascertain the stage of cervical cancer.
For women, cervical cancer is a typically malignant tumor. In recent years, there has been an apparent trend of rejuvenation along with an increase in morbidity and mortality. The only cancer that has a clear etiology and may be cured with early detection is cervical cancer. For instance, the CerviClear test, developed by New Horizon Health, is the world's first urine-based HPV detection and cervical cancer screening test.
It accomplishes non-invasive home-based urine self-sampling and is the only solution that completely covers all 14 high-risk HPV viruses. The product is eligible to be introduced in Hong Kong and the Greater Bay Area because it already possesses a CE Mark.
Cervical cancer is one of the most preventable cancers, it accounts for nearly 77,000 deaths among Indian women each year. For instance, in April 2023, the Cancer Awareness Prevention and Early Detection Trust (CAPED), a non-profit organization dedicated to promoting cancer awareness, prevention, and early detection, and Roche Diagnostics India signed a Memorandum of Understanding (MoU).
The relationship with CAPED is one recent initiative by Roche Diagnostics India to remove the societal stigma associated with the disease and raise awareness about cervical cancer screening. Roche Diagnostics India is dedicated to reducing the incidence of cervical cancer internationally.
The price of cervical cancer diagnostic tests can vary depending on several variables, including the particular test, location, the environment for the medical facility and the healthcare system in existence. Pap tests can cost from $20 and $100, depending place and healthcare professionals.
In addition, HPV DNA tests cost from $50 to $200 or more, depending on the lab and the precise testing technique employed. A colposcopy operation might cost between $200 and $800, depending on the area, the healthcare professional and any extra procedures carried out during the examination.
The COVID-19 pandemic has had a significant impact on the cervical cancer diagnostics market. The pandemic has put pressure on healthcare systems, which has restricted the availability of cervical cancer diagnostic services.
Delays in diagnostic testing, such as Pap smear tests, HPV tests, colposcopies and biopsies, have been attributed to a lack of resources, overburdened healthcare institutions and the redirection of workers to COVID-19 response operations.
As of 2023, the COVID-19 situation is recovering and all patients can access healthcare facilities driving the cervical cancer diagnostics market.
The impact of the Russia-Ukraine war on the cervical cancer diagnostics market is complex and multifaceted. People may be displaced by the combat, transportation may be disrupted, and military checkpoints may be set up. These obstacles may limit access to medical facilities, making it difficult for people to get prompt cervical cancer diagnoses and other healthcare services.
In addition, healthcare resources and efforts were redirected during times of conflict to focus on trauma care, emergency response and urgent medical needs. This results in fewer public health measures, such as awareness campaigns and cervical cancer screening programs, which would lower screening rates and postpone diagnosis.
The global cervical cancer diagnostics market is segmented based on test type, age group, distribution channel, end-user and region.
The HPV DNA test segment accounted for the 2nd highest market stake accounting for approximately 27.6% of the cervical cancer diagnostics market in 2022. An HPV test examines a sample of cells to see if they have a high-risk form of the virus. If such an infection persists for a long time, it may alter cervical cells and result in cervical cancer.
For instance, in September 2022, to test for high-risk HPV types in individuals, Mylab Discovery Solutions introduced the "PathoDetect HPV Detection Test," a real-time PCR-based screening tool. 'PathoDetect HPV Detection Test' is a regulatory authority-approved test that finds and distinguishes the presence of high-risk HPV strains, such as strains 16 and 18, which are responsible for the majority of cervical cancers.
Increasing Collaborations and Partnerships Among the Key Players, Increasing Prevalence of Cervical Cancer and Advancement in Cervical Cancer Diagnostics Dominate the North American Region.
North America is expected to dominate the cervical cancer diagnostics market, accounting for around 38.9% of the market share. As per the article published in the International Journal of Gynecological Cancer in 2022, when examining the trends over time, it was discovered that the prevalence of cervical cancer in its remote stages increased annually at a rate of 1.3% (p 0.001). Cervical adenocarcinoma has the highest growth, with an average yearly percent change of 2.9% (p 0.001).
White women in the South aged 40-44 have the biggest increase in distant cervical cancer at a rate of 4.5% annually (p0.001), according to an intersecting analysis of race, location and age.
The major global players in the market include: QIAGEN Becton, Dickinson and Company F. Hoffmann-La Roche Ltd. Guided Therapeutics Olympus Cardinal Health Siemens Healthcare Hologic, Inc. Quest Diagnostics Abbott Laboratories among others.
The Global Cervical Cancer Diagnostics Market Report Would Provide Approximately 61 Tables, 60 Figures and 195 pages.
LIST NOT EXHAUSTIVE